Risks of gene therapy should be weighed against lack of alternatives for many diseases
BMJ
.
2005 Apr 2;330(7494):791.
doi: 10.1136/bmj.330.7494.791-a.
Authors
Robert E MacLaren
,
Robin R Ali
,
Adrian J Thrasher
PMID:
15802733
PMCID:
PMC555925
DOI:
10.1136/bmj.330.7494.791-a
No abstract available
Publication types
Comment
Letter
MeSH terms
Genetic Therapy / adverse effects*
Humans
Leukemia, T-Cell / therapy
Risk Assessment
Risk Factors
Severe Combined Immunodeficiency / therapy